Signs, Symptoms, And Pathophysiology - NAPLEX

1. A 72-year-old woman (58 kg, 160 cm) presents with new confusion, nausea, and unsteady gait for 2 days. Medical history: depression, hypertension, osteoarthritis. Current medications: sertraline 100 mg daily (recently increased from 50 mg 10 days ago), hydrochlorothiazide 25 mg daily, acetaminophen 650 mg every 6 hours as needed. Allergies: none. Labs: sodium 122 mEq/L (normal 135–145), potassium 3.9 mEq/L, SCr 0.9 mg/dL, glucose 96 mg/dL. What is the most likely cause of these symptoms based on the patient's medication list?
   Answer: Sertraline-induced syndrome of inappropriate antidiuretic hormone secretion (SIADH) causing hyponatremia This question evaluates the recognition of medication-induced hyponatremia, specifically SIADH from SSRIs in an elderly patient. The key lab value is sodium at 122 mEq/L, with symptoms of confusion, nausea, and unsteady gait following a sertraline dose increase. Sertraline-induced SIADH is the best choice because SSRIs can stimulate inappropriate antidiuretic hormone release, leading to water retention, dilutional hyponatremia, and neurologic symptoms. Acetaminophen-induced liver failure would show elevated liver enzymes and coagulopathy, not isolated hyponatremia, while hydrochlorothiazide-induced hyperkalemia is unlikely with normal potassium and doesn't cause confusion primarily. Sertraline-induced serotonin syndrome presents with hyperthermia, clonus, and autonomic instability, not matching this euvolemic hyponatremia. Clinically, monitoring electrolytes after SSRI initiation or dose changes is crucial in older adults due to higher SIADH risk. A framework for hyponatremia involves assessing volume status and urine osmolality to differentiate causes like SIADH from dehydration or heart failure.
2. A 52-year-old female (68 kg) with asthma presents with acute worsening shortness of breath and wheezing shortly after taking a new pain reliever for headache. Medical history: asthma, chronic rhinosinusitis with nasal polyps. Current medications: budesonide/formoterol inhaler 2 puffs twice daily, albuterol inhaler as needed. Allergies: none reported. Labs: SCr 0.7 mg/dL (0.6–1.1). She took ibuprofen 400 mg 30 minutes ago and now has chest tightness and audible wheeze. Which condition is most consistent with this patient's symptoms?
   Answer: Aspirin/NSAID-exacerbated respiratory disease due to leukotriene overproduction after cyclooxygenase-1 inhibition This question evaluates understanding of aspirin-exacerbated respiratory disease (AERD) pathophysiology. The key features are acute bronchospasm after NSAID ingestion in a patient with asthma and chronic rhinosinusitis with nasal polyps. Aspirin/NSAID-exacerbated respiratory disease due to leukotriene overproduction after cyclooxygenase-1 inhibition (A) correctly describes AERD, where COX-1 blockade shunts arachidonic acid metabolism toward leukotriene synthesis, causing bronchospasm in susceptible individuals. IgE-mediated penicillin allergy (B) is unrelated to NSAIDs. Beta-blocker bronchospasm (C) requires beta-blocker exposure. ACE inhibitor cough (D) develops gradually, not acutely. The classic triad of asthma, nasal polyposis, and NSAID sensitivity, with acute bronchospasm following ibuprofen ingestion, confirms AERD diagnosis and highlights the importance of avoiding all NSAIDs in these patients.
3. A 38-year-old woman (64 kg) presents with palpitations, heat intolerance, anxiety, and unintentional weight loss for 2 months. Medical history: none. Current medications: none. Allergies: none. Labs: TSH <0.01 mIU/L (normal 0.4–4.0), free T4 high, ALT 26 U/L, SCr 0.7 mg/dL. Which pathophysiological mechanism explains this patient's condition?
   Answer: Autoantibodies stimulating the thyroid-stimulating hormone receptor leading to increased thyroid hormone production This question assesses the pathophysiology of hyperthyroidism based on symptoms and thyroid labs. The key symptoms are palpitations, heat intolerance, anxiety, and weight loss, with TSH <0.01 mIU/L and high free T4. Autoantibodies stimulating the TSH receptor is the best choice because it describes Graves' disease, leading to unregulated thyroid hormone production and hypermetabolic state. Thyroid destruction causes hypothyroidism, while reduced T4 to T3 conversion occurs in non-thyroidal illness, and pituitary failure yields low TSH with low T4. Clinically, antithyroid drugs like methimazole control hormone synthesis, with beta-blockers for symptom relief. A framework involves measuring thyroid antibodies to confirm autoimmune etiology and monitoring for complications like atrial fibrillation.
4. A 50-year-old man (95 kg) presents with severe epigastric pain radiating to the back with nausea and vomiting. Medical history: hypertriglyceridemia, alcohol use disorder. Current medications: fenofibrate 145 mg daily (nonadherent). Allergies: none. Labs: lipase 1,200 U/L (normal 0–160), triglycerides 1,100 mg/dL (normal <150), AST 40 U/L, ALT 38 U/L, SCr 1.0 mg/dL. Which condition is most consistent with this patient's symptoms?
   Answer: Acute pancreatitis This question tests diagnosis of abdominal pain syndromes based on location, radiation, and labs in a patient with risk factors. The key symptoms are severe epigastric pain radiating to the back with nausea, and elevated lipase at 1,200 U/L. Acute pancreatitis is the best choice because it involves pancreatic enzyme autodigestion, often from hypertriglyceridemia or alcohol, causing inflammation and high lipase. Acute cholecystitis localizes to right upper quadrant with Murphy's sign, while GERD causes burning without radiation, and myocardial infarction may mimic but lacks high lipase. A clinical insight is using Ranson's criteria to assess pancreatitis severity and prognosis. Decision-making involves NPO status, fluids, and addressing etiologies like triglycerides with fibrates.
5. An 80-year-old male (75 kg) presents for medication review after a fall. Medical history: benign prostatic hyperplasia, insomnia, osteoarthritis, hypertension. Current medications: tamsulosin 0.4 mg nightly, diphenhydramine 50 mg nightly for sleep, lisinopril 10 mg daily, acetaminophen 1000 mg three times daily as needed. Allergies: none. Labs: SCr 1.2 mg/dL (0.7–1.3), sodium 138 mEq/L (135–145). He reports dry mouth and urinary hesitancy worsening since starting the sleep aid. What is the most likely cause of these symptoms based on the patient's medication list?
   Answer: Anticholinergic effects from diphenhydramine worsening urinary retention and causing dry mouth This question assesses recognition of anticholinergic adverse effects in elderly patients. The key findings are dry mouth and urinary hesitancy worsening after starting diphenhydramine in an elderly man with BPH. Anticholinergic effects from diphenhydramine worsening urinary retention and causing dry mouth (A) is correct because first-generation antihistamines have significant antimuscarinic activity, causing xerostomia and bladder dysfunction, particularly problematic in elderly males with prostatic enlargement. Excess alpha-1 agonism from tamsulosin (B) is incorrect as tamsulosin is an alpha-1 antagonist that improves urinary flow. Hyponatremia (C) is not present (sodium 138). Acetaminophen-induced cholestasis (D) is rare and wouldn't cause these specific symptoms. The temporal relationship between diphenhydramine initiation and symptom onset, combined with classic anticholinergic effects in a vulnerable population, confirms medication-induced adverse effects requiring discontinuation.
6. A 23-year-old woman (55 kg) presents with 1 week of vaginal itching and thick, white, "cottage cheese"-like discharge without odor. Medical history: none. Current medications: recently completed amoxicillin 500 mg three times daily for 7 days for strep throat. Allergies: none. Pregnancy test: negative. What is the first-line treatment for this condition considering the patient's presentation?
   Answer: Fluconazole 150 mg by mouth once This question examines management of vulvovaginal candidiasis post-antibiotic use in a non-pregnant woman. The key symptoms are vaginal itching and thick, white, cottage cheese-like discharge without odor, following amoxicillin. Fluconazole 150 mg once is the best choice because it inhibits fungal ergosterol synthesis, effectively treating Candida overgrowth from antibiotic-induced flora disruption. Metronidazole targets bacterial vaginosis with malodorous discharge, while doxycycline treats chlamydia, and acyclovir is for herpes without matching symptoms. A transferable insight is recognizing post-antibiotic candidiasis and confirming with wet mount if needed. Clinically, decision-making involves single-dose azoles for uncomplicated cases, with longer courses for recurrence or diabetes.
7. A 64-year-old man (86 kg) with type 2 diabetes presents with shakiness, sweating, and confusion 2 hours after lunch. Medical history: type 2 diabetes, chronic kidney disease stage 4. Current medications: glyburide 10 mg daily, metformin 500 mg twice daily, lisinopril 10 mg daily. Allergies: none. Fingerstick glucose: 48 mg/dL. Labs: SCr 2.8 mg/dL, eGFR 22 mL/min/1.73 $m^2$. What is the most likely cause of these symptoms based on the patient's medication list?
   Answer: Glyburide accumulation in renal impairment causing prolonged hypoglycemia This question assesses medication-related hypoglycemia in diabetes with renal impairment. The key finding is fingerstick glucose of 48 mg/dL with symptoms of shakiness, sweating, and confusion, in a patient with eGFR 22 mL/min/1.73 $m^2$. Glyburide accumulation in renal impairment causing prolonged hypoglycemia is the best choice because sulfonylureas like glyburide have active metabolites cleared by kidneys, leading to excessive insulin release and low glucose. Metformin doesn't cause hypoglycemia and is not the primary issue, while lisinopril lacks hypoglycemic effects, and diabetic ketoacidosis involves hyperglycemia with acidosis. A transferable insight is preferring shorter-acting sulfonylureas or alternative agents in CKD to avoid hypoglycemia. Clinically, decision-making involves immediate glucose administration and deprescribing high-risk drugs in renal dysfunction.
8. A 63-year-old man (84 kg) with chronic obstructive pulmonary disease (COPD) presents with increased dyspnea, increased sputum volume, and purulent sputum for 4 days. Medical history: COPD, type 2 diabetes. Current medications: umeclidinium/vilanterol 1 inhalation daily, albuterol HFA as needed, metformin 1000 mg twice daily. Allergies: none. Vitals: afebrile, SpO2 91% on room air. Labs: SCr 1.0 mg/dL, glucose 140 mg/dL. What is the first-line treatment for this condition considering the patient's presentation?
   Answer: Start oral prednisone (e.g., 40 mg daily for 5 days) and consider antibiotics due to increased sputum purulence This question examines management of COPD exacerbations based on symptom changes and guidelines. The key symptoms are increased dyspnea, sputum volume, and purulence, indicating a likely bacterial trigger. Starting oral prednisone and considering antibiotics is the best choice because systemic corticosteroids reduce inflammation and recovery time, with antibiotics for purulent sputum to target bacterial superinfection. Inhaled corticosteroid monotherapy lacks evidence for acute exacerbations, while oseltamivir is for influenza, and long-term oxygen is for chronic hypoxemia. A transferable insight is using the Anthonisen criteria (dyspnea, sputum volume, purulence) to guide antibiotic use. Clinically, decision-making involves assessing for hospitalization with ABGs if SpO2 <90%.
9. A 52-year-old man (88 kg) presents with severe right first metatarsophalangeal joint pain, redness, and swelling that started overnight. Medical history: hypertension, chronic kidney disease stage 3. Current medications: hydrochlorothiazide 25 mg daily, losartan 50 mg daily. Allergies: none. Labs: uric acid 9.8 mg/dL (normal 3.5–7.2), SCr 1.9 mg/dL, eGFR 40 mL/min/1.73 $m^2$, potassium 4.3 mEq/L. Which condition is most consistent with this patient's symptoms?
   Answer: Acute gout flare due to monosodium urate crystal-induced inflammation This question assesses diagnosis of acute gout based on joint symptoms and lab findings in a patient with risk factors. The key symptoms are sudden severe pain, redness, and swelling in the first metatarsophalangeal joint, with elevated uric acid at 9.8 mg/dL. Acute gout flare due to monosodium urate crystal-induced inflammation is the best choice because hyperuricemia leads to crystal deposition in joints, triggering acute synovitis, especially with diuretics like hydrochlorothiazide. Septic arthritis typically involves fever and systemic signs, while osteoarthritis causes chronic pain without acute redness, and rheumatoid arthritis is symmetric with morning stiffness. Clinically, confirming gout via synovial fluid analysis for crystals distinguishes it from mimics like pseudogout. A decision-making framework includes using colchicine or NSAIDs for acute flares and urate-lowering therapy for prevention in recurrent cases.
10. A 45-year-old male (110 kg, 178 cm) presents for hypertension follow-up. Medical history: hypertension, gout. Current medications: hydrochlorothiazide 25 mg daily, allopurinol 300 mg daily, ibuprofen 400 mg as needed. Allergies: none. Blood pressure today is 156/94 mmHg. Labs: SCr 1.0 mg/dL (0.7–1.3), potassium 3.3 mEq/L (3.5–5.0), uric acid 9.2 mg/dL (3.5–7.2). He reports a recent gout flare. Which adjustment is needed in his therapy plan?
    Answer: Discontinue hydrochlorothiazide and initiate losartan due to gout and hypokalemia risk This question assesses understanding of thiazide diuretic adverse effects and appropriate therapeutic modifications. The key findings are uncontrolled hypertension, hypokalemia, hyperuricemia, and recent gout flare in a patient on hydrochlorothiazide. Discontinuing hydrochlorothiazide and initiating losartan due to gout and hypokalemia risk (A) is correct because thiazides worsen both conditions by causing potassium wasting and increasing uric acid reabsorption. Increasing hydrochlorothiazide (B) would worsen both adverse effects. Adding potassium chloride (C) is incorrect because thiazides raise, not lower, uric acid levels. Switching allopurinol to probenecid (D) is inappropriate as probenecid is less effective with reduced GFR and doesn't address the thiazide issue. The clinical decision to switch to an ARB addresses hypertension while avoiding metabolic complications, demonstrating appropriate drug selection based on patient-specific factors.
11. A 66-year-old male (88 kg) with chronic obstructive pulmonary disease (COPD) presents with increased dyspnea, wheezing, and increased sputum volume and purulence for 3 days. Medical history: COPD (FEV1 45% predicted), hypertension. Current medications: tiotropium inhaled 2 puffs daily, albuterol inhaler 2 puffs every 4–6 hours as needed, amlodipine 10 mg daily. Allergies: none. Labs: SCr 0.9 mg/dL (0.7–1.3). He is afebrile, oxygen saturation 92% on room air, and can speak in full sentences. What is the first-line treatment for this condition considering the patient's presentation?
    Answer: Start oral prednisone and add an antibiotic due to increased sputum purulence This question tests management of acute COPD exacerbation based on clinical presentation. The key features are increased dyspnea, wheezing, and purulent sputum in a COPD patient who remains afebrile and hemodynamically stable. Starting oral prednisone and adding an antibiotic due to increased sputum purulence (A) is correct because GOLD guidelines recommend systemic corticosteroids for all COPD exacerbations and antibiotics when sputum purulence increases, indicating bacterial infection. Inhaled fluticasone monotherapy (B) is inadequate for acute exacerbations requiring systemic corticosteroids. Chronic azithromycin (C) is for prevention, not acute treatment. Theophylline (D) is not first-line and has a narrow therapeutic window. The combination of systemic corticosteroids for inflammation reduction and antibiotics for likely bacterial superinfection represents evidence-based management of moderate COPD exacerbation.
12. A 58-year-old male (92 kg) with type 2 diabetes presents with 3 months of burning/tingling pain in both feet that is worse at night and decreased sensation to monofilament testing. Medical history: type 2 diabetes, hypertension, dyslipidemia. Current medications: metformin 1000 mg twice daily, insulin glargine 30 units nightly, lisinopril 20 mg daily, atorvastatin 40 mg nightly. Allergies: none. Labs: hemoglobin A1c 9.4% (<7%), SCr 1.0 mg/dL (0.7–1.3), potassium 4.3 mEq/L (3.5–5.0), alanine aminotransferase (ALT) 28 U/L (7–56). Which pathophysiological mechanism explains this patient's condition?
    Answer: Chronic hyperglycemia causing microvascular ischemia and oxidative injury to peripheral nerves This question assesses understanding of diabetic peripheral neuropathy pathophysiology. The key finding is bilateral burning/tingling pain with decreased sensation in a patient with poorly controlled diabetes (A1c 9.4%). Chronic hyperglycemia causing microvascular ischemia and oxidative injury to peripheral nerves (B) correctly describes the pathophysiology of diabetic neuropathy, where sustained hyperglycemia leads to metabolic and vascular damage to nerve fibers. Autoimmune demyelination (A) describes Guillain-Barré syndrome, which presents acutely with ascending weakness, not chronic sensory symptoms. Acute urate crystal deposition (C) describes gout, which causes joint pain, not neuropathic symptoms. Excess acetylcholine (D) relates to myasthenia gravis, which causes muscle weakness, not sensory neuropathy. The chronic nature, distribution pattern, and association with poor glycemic control confirm diabetic neuropathy as the underlying mechanism.
13. A 57-year-old woman (72 kg) presents with persistent dry cough that began 3 weeks after starting a new blood pressure medication. Medical history: hypertension. Current medications: lisinopril 20 mg daily (started 1 month ago). Allergies: none. Labs: SCr 0.9 mg/dL, potassium 4.8 mEq/L. Which pathophysiological mechanism explains this patient's condition?
    Answer: Increased bradykinin levels due to angiotensin-converting enzyme inhibition This question evaluates adverse effects of antihypertensive medications, focusing on cough mechanisms. The key symptom is persistent dry cough starting weeks after lisinopril initiation, without other abnormalities. Increased bradykinin levels due to ACE inhibition is the best choice because ACE breaks down bradykinin, and its inhibition leads to accumulation, causing airway irritation and cough. Beta-2 blockade describes beta-blocker asthma exacerbation, while immune complexes relate to drug-induced lupus, and dopamine blockade causes parkinsonism. Clinically, switching to an ARB resolves cough while maintaining efficacy. A framework includes considering ACE inhibitor cough in differential for new respiratory symptoms and confirming with drug timeline.
14. A 41-year-old man (90 kg) presents with 3 days of watery diarrhea and abdominal cramping after completing clindamycin 300 mg four times daily for 10 days for a dental infection. Medical history: none. Current medications: none besides recent antibiotic. Allergies: none. Labs: white blood cell count 14,500/$mm^3$ (normal 4,000–11,000), SCr 1.0 mg/dL. Which condition is most consistent with this patient's symptoms?
    Answer: Clostridioides difficile infection due to antibiotic-associated disruption of gut flora This question tests recognition of antibiotic-associated diarrhea, specifically Clostridioides difficile infection. The key symptoms are watery diarrhea and abdominal cramping following recent clindamycin use, with leukocytosis. Clostridioides difficile infection due to antibiotic-associated gut flora disruption is the best choice because broad-spectrum antibiotics like clindamycin allow C. difficile overgrowth, toxin production, and colitis. Acute pancreatitis presents with epigastric pain and elevated lipase, while irritable bowel syndrome lacks post-antibiotic timing and fever, and appendicitis causes right lower quadrant pain with rebound tenderness. Clinically, testing for C. difficile toxins via PCR or EIA is essential in post-antibiotic diarrhea. A framework includes avoiding high-risk antibiotics in susceptible patients and using fidaxomicin or vancomycin for treatment to reduce recurrence.
15. A 27-year-old woman (60 kg) presents with 2 days of pruritic hives and facial swelling after starting trimethoprim-sulfamethoxazole for a skin infection. Medical history: none. Current medications: trimethoprim-sulfamethoxazole double strength 1 tablet twice daily (started 3 days ago). Allergies: none previously known. Vitals: BP 118/72, HR 92, SpO2 99% on room air; no wheezing. Labs: SCr 0.8 mg/dL, AST/ALT normal. Which pathophysiological mechanism explains this patient's condition?
    Answer: Type I hypersensitivity mediated by immunoglobulin E with mast cell degranulation This question evaluates the immunological mechanism of drug allergies, specifically immediate reactions. The key symptoms are pruritic hives and facial swelling shortly after starting trimethoprim-sulfamethoxazole, without respiratory compromise. Type I hypersensitivity mediated by IgE with mast cell degranulation is the best choice because it involves allergen-IgE binding, releasing histamine and causing urticaria and angioedema. Type II hypersensitivity targets cells like in hemolytic anemia, while type III causes serum sickness with joint involvement, and type IV is delayed without immediate hives. Clinically, discontinuing the offending drug and using antihistamines or epinephrine for severe cases manages anaphylaxis risk. A framework includes documenting allergies and cross-reactivity, such as sulfa drugs, to guide future prescribing.
16. A 73-year-old man (70 kg) presents with decreased urine output and swelling after 5 days of starting naproxen 500 mg twice daily for back pain. Medical history: heart failure with reduced ejection fraction, chronic kidney disease stage 3, hypertension. Current medications: lisinopril 20 mg daily, furosemide 40 mg daily, carvedilol 12.5 mg twice daily, naproxen 500 mg twice daily (new). Allergies: none. Labs: SCr increased from 1.4 to 2.2 mg/dL, potassium 5.6 mEq/L, sodium 134 mEq/L. What is the most likely cause of these symptoms based on the patient's medication list?
    Answer: Triple-whammy acute kidney injury from ACE inhibitor plus diuretic plus nonsteroidal anti-inflammatory drug reducing renal perfusion This question assesses drug-induced acute kidney injury from combination therapy affecting renal perfusion. The key symptoms and labs are decreased urine output, swelling, and SCr rise from 1.4 to 2.2 mg/dL after adding naproxen. Triple-whammy AKI from ACE inhibitor, diuretic, and NSAID is the best choice because they synergistically reduce glomerular filtration via afferent constriction, dehydration, and efferent dilation inhibition. Carvedilol doesn't cause direct nephrotoxicity, while furosemide causes hypokalemia not hyperkalemia, and lisinopril doesn't form stones. Clinically, discontinuing the NSAID and monitoring renal function reverses prerenal AKI. A framework involves avoiding this combination in elderly or CKD patients and checking SCr after NSAID initiation.
17. A 28-year-old female (70 kg) presents with 6 weeks of fatigue, heat intolerance, palpitations, and unintentional weight loss. Physical exam notes a fine tremor and a diffusely enlarged, nontender thyroid. Medical history: none. Current medications: none. Allergies: none. Labs: thyroid-stimulating hormone (TSH) <0.01 mIU/L (0.4–4.0), free thyroxine (free T4) 2.8 ng/dL (0.8–1.8). Which condition is most consistent with this patient's symptoms?
    Answer: Graves disease causing thyroid hormone overproduction This question evaluates recognition of hyperthyroid conditions based on clinical and laboratory findings. The key features are heat intolerance, palpitations, weight loss, tremor, diffusely enlarged thyroid, suppressed TSH (<0.01), and elevated free T4. Graves disease causing thyroid hormone overproduction (B) is correct as it presents with these classic hyperthyroid symptoms plus diffuse goiter due to TSH receptor antibodies stimulating the entire gland. Primary hypothyroidism (A) would show elevated TSH and low T4 with opposite symptoms. Subacute thyroiditis (C) causes a painful, tender thyroid, which this patient lacks. Secondary hypothyroidism (D) would show low TSH and low T4, not elevated T4. The combination of hyperthyroid symptoms, diffuse painless goiter, and biochemical hyperthyroidism strongly suggests Graves disease as the underlying autoimmune etiology.
18. A 67-year-old man (80 kg) with atrial fibrillation on warfarin presents with dark stools and lightheadedness. Medical history: atrial fibrillation, osteoarthritis, gastroesophageal reflux disease. Current medications: warfarin (variable dosing; target INR 2–3), ibuprofen 600 mg three times daily started 1 week ago, omeprazole 20 mg daily. Allergies: none. Labs: INR 3.4 (normal 0.8–1.2), hemoglobin 9.8 g/dL (baseline 13), SCr 1.1 mg/dL, AST/ALT normal. What is the most likely cause of these symptoms based on the patient's medication list?
    Answer: Warfarin and ibuprofen increasing bleeding risk via anticoagulation plus platelet inhibition and gastrointestinal mucosal injury This question assesses identification of drug interactions increasing bleeding risk in a patient on anticoagulation. The key symptoms and labs are dark stools, lightheadedness, INR 3.4, and decreased hemoglobin, following ibuprofen addition to warfarin. Warfarin and ibuprofen interaction is the best choice because ibuprofen inhibits platelets and causes GI mucosal injury, potentiating warfarin's anticoagulation and elevating INR, leading to GI bleeding. Omeprazole-induced vitamin K deficiency is unlikely as it doesn't affect clotting factors directly, while warfarin-induced thrombosis occurs early in therapy, not with supratherapeutic INR. Ibuprofen causing hemolytic anemia would show schistocytes and low haptoglobin, not seen here. Clinically, monitoring INR and avoiding NSAIDs in warfarin patients prevents such interactions, with PPIs for gastroprotection if needed. A framework involves reviewing medication lists for CYP2C9 inhibitors or antiplatelets when bleeding occurs on warfarin.
19. A 34-year-old woman (62 kg) presents with 1 day of dysuria, urinary frequency, and suprapubic discomfort without fever or flank pain. Medical history: none. Current medications: combined oral contraceptive (ethinyl estradiol/levonorgestrel) 1 tablet daily. Allergies: none. Labs: urine dipstick positive for leukocyte esterase and nitrites; SCr 0.7 mg/dL. What is the first-line treatment for this condition considering the patient's presentation?
    Answer: Nitrofurantoin 100 mg by mouth twice daily for 5 days This question examines the management of uncomplicated cystitis in a young woman, emphasizing first-line antibiotic selection based on guidelines. The key findings are dysuria, frequency, suprapubic discomfort, and positive urine dipstick for leukocyte esterase and nitrites without systemic symptoms. Nitrofurantoin is the best choice because it achieves high urinary concentrations effective against common uropathogens like E. coli, with a short 5-day course minimizing resistance in uncomplicated cases. Ciprofloxacin is reserved for complicated UTIs or resistance due to broader spectrum and resistance concerns, while amoxicillin-clavulanate is not first-line for cystitis and vancomycin is intravenous for resistant infections. A transferable insight is that uncomplicated UTIs in women can often be treated empirically based on local resistance patterns without culture. Clinically, assessing for complicating factors like pregnancy or diabetes guides duration and choice, with follow-up if symptoms persist.
20. A 58-year-old man (105 kg, 175 cm) with type 2 diabetes presents for follow-up because home glucose readings remain high. Medical history: type 2 diabetes, coronary artery disease, chronic kidney disease stage 3. Current medications: metformin 1000 mg twice daily, insulin glargine 20 units nightly, lisinopril 10 mg daily, atorvastatin 40 mg nightly, aspirin 81 mg daily. Allergies: none. Labs: A1C 9.2% (goal <7%), fasting glucose 190 mg/dL, SCr 1.8 mg/dL, estimated glomerular filtration rate (eGFR) 38 mL/min/1.73 $m^2$, potassium 4.6 mEq/L, ALT 28 U/L. Which adjustment is needed in the patient's therapy plan?
    Answer: Add a sodium-glucose cotransporter-2 (SGLT2) inhibitor with renal and cardiovascular benefit if no contraindications This question tests optimization of therapy in type 2 diabetes with chronic kidney disease and cardiovascular risk, focusing on evidence-based additions. The key lab values are A1C 9.2%, eGFR 38 mL/min/1.73 $m^2$, and uncontrolled hyperglycemia despite current regimen. Adding an SGLT2 inhibitor is the best choice because it provides glycemic control, renal protection via reduced glomerular hyperfiltration, and cardiovascular benefits in patients with DKD and CAD. Discontinuing metformin is not immediately required as it can be used at eGFR >30 with dose adjustment, while switching to regular insulin lacks rationale and switching off lisinopril would worsen renal outcomes. Stopping lisinopril is inappropriate as ACE inhibitors are nephroprotective in diabetes. A clinical insight is prioritizing agents like SGLT2 inhibitors or GLP-1 agonists in diabetes with comorbidities for multifaceted benefits beyond glucose control. Decision-making should involve assessing eGFR thresholds for medication safety and incorporating cardiorenal protective therapies per guidelines.

Start this quiz